National Institute for Communicable Diseases
Centre for Respiratory Diseases and Meningitis
Anne von Gottberg is currently the laboratory lead for the Centre for Respiratory Diseases and Meningitis at the National Institute for Communicable Diseases, Johannesburg, South Africa and Associate Professor within the School of Pathology, Faculty of the Health Sciences, University of the Witwatersrand, Johannesburg; and Honorary Professor, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town. She leads a laboratory team responsible for reference diagnostics for respiratory and meningeal pathogens nationally and regionally. The laboratory is the regional reference laboratory for the World Health Organization (WHO) Vaccine-preventable Invasive Bacterial Diseases (VP-IBD) Coordinated Global Surveillance Network for the southern African region; a National Influenza Centre (NIC); and a WHO RSV and SARS-CoV-2 Reference Laboratory. Her main interests include surveillance for meningitis and respiratory pathogens, assessing vaccine effectiveness where relevant. She has authored or co-authored more than 200 articles in peer-reviewed journals. In addition, she supervises a number of Masters and PhD students. Dr von Gottberg obtained her MBBCh and PhD at the University of the Witwatersrand, and trained for her specialisation in clinical microbiology (FC Path[SA] MICRO) at the National Health Laboratory Service (former South African Institute for Medical Research) and at the University of the Witwatersrand.

Moderator of 2 Sessions

Meet-the-Expert Session 06: What’s the Latest With Serotype Replacement?

Session Type
Meet-the-Expert Session
Date
Tue, 21.06.2022
Session Time
13:30 - 14:30
Room
Grand Ballroom West
Session Description
In this session we will present data from our respective countries on the main serotypes that are emerging to be dominant in the post higher valency vaccine use era (i.e. post 13vPCV/10vPCV) and discuss the interpretation of that data in terms of serotype replacement.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.

Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.
Session Type
Parallel Session
Date
Wed, 22.06.2022
Session Time
15:05 - 16:50
Room
Grand Ballroom Centre
Session Description
Please note: Each presentation is followed by about 3 minutes of Q&A. The audience is encouraged to send questions to the speakers from the beginning of their presentations. Q&A time is included in each speaker’s presentation duration, accounting for at least 25% active learning for the maximum registrants anticipated.

Presenter of 1 Presentation

Beyond PCV Introduction for Infants: Next Steps in Disease Control in Africa (ID 34)

Session Type
Plenary Session
Date
Mon, 20.06.2022
Session Time
09:00 - 10:30
Room
Grand Ballroom East
Lecture Time
09:44 - 10:06